Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Type
Public
HQ
Princeton, US
Founded
2002
Size (employees)
90 (est)
Advaxis was founded in 2002 and is headquartered in Princeton, US

Key People at Advaxis

Anthony Lombardo

Anthony Lombardo

Interim CEO
Thomas J. McKearn

Thomas J. McKearn

Director
Roni A. Appel

Roni A. Appel

Director
Richard Berman

Richard Berman

Director
Robert G. Petit

Robert G. Petit

Executive Vice President and Chief Scientific Officer

Advaxis Office Locations

Advaxis has an office in Princeton
Princeton, US (HQ)
305 College Rd E

Advaxis Data and Metrics

Advaxis Financial Metrics

Advaxis's revenue was reported to be $3.4 m in Q2, 2017
USD

Revenue (Q2, 2017)

3.4 m

Net income (Q2, 2017)

(20.5 m)

EBIT (Q2, 2017)

(20.7 m)

Market capitalization (22-Sep-2017)

185.6 m

Cash (31-Oct-2016)

112.8 m
Advaxis's current market capitalization is $185.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.9 m1 m4 m

Revenue growth, %

(46%)

R&D expense

48.8 m

General and administrative expense

31.7 m
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

250 k3.8 m3.4 m

R&D expense

7.3 m13.1 m8.8 m10.1 m13.6 m16.3 m

General and administrative expense

6.3 m7.1 m6.8 m6.4 m7.3 m7.8 m

Operating expense total

13.6 m20.2 m15.6 m16.6 m21 m24.1 m
USDFY, 2013FY, 2014FY, 2016

Cash

20.6 m17.6 m112.8 m

Accounts Receivable

80.1 k

Current Assets

20.8 m20.5 m159.9 m

Total Assets

23.6 m23.4 m169 m
USDQ3, 2014Q1, 2015Q2, 2015

Cash

22.1 m30.6 m45.9 m

Current Assets

23.3 m31.5 m48.6 m

Total Assets

26.1 m34.5 m51.7 m

Accounts Payable

1.7 m1.5 m3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(20 m)(16.5 m)(73.6 m)

Depreciation and Amortization

19.3 k27.6 k283.5 k

Accounts Receivable

65.2 k

Accounts Payable

(1.9 m)8.4 m
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(13.6 m)(19.8 m)(15.5 m)(16.5 m)(17.1 m)(20.5 m)

Accounts Receivable

152.3 k164.6 k140.2 k181 k192.3 k

Accounts Payable

2.2 m843.5 k5.6 m2.6 m3.5 m9.7 m
Show all financial metrics

Advaxis Market Value History

Traffic Overview of Advaxis

Advaxis Online and Social Media Presence

Advaxis Company Life and Culture

You may also be interested in